ipamorelin and retatrutide (RUO) | Selective GHS-R1a Agonist Current research stack: CJC-1295/Ipamorelin, Retatrutide,

Description

How GLP-1 Microdosing Works Sub-therapeutic initiation dosing begins well below standard protocols, reducing early GI side-effect risk Gradual dose escalation titration is slower than standard schedules, allowing adaptation at a comfortable pace Maintained metabolic benefits even at lower doses, GLP-1 receptor activation improves appetite regulation, insulin sensitivity, and glucose metabolism Continuous personalized optimization doses are adjusted based on clinical response, weight trajectory, and patient tolerance Who Is Microdosing GLP-1 Therapy the Right Fit For in Irvine

Methods: Only clinical trials with endpoints assessed by liver histology were included for a robust evaluation of therapeutic efficacy

These limitations dont prevent useful comparison, but they do require careful interpretation rather than simple number-to-number comparison

Oct 26: Eli Lilly won FDA approval Thursday for Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active ulcerative colitis (UC), marking the companys first approved drug for a type of inflammatory bowel disease